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While the ethical debate on clinical trials is often focused
on informed consent and related issues, estimation of the re-
quired sample size is usually not evaluated as to its ethical
implications. However, these implications can be consider-
able in terms of subjects burdened with experimental inter-
ventions and of the surplus number of needed primary end-
points or adverse outcomes before superiority or inferiority
of an intervention is accepted.
In a standard randomised controlled trial the outcome of
a group subjected to the studied intervention of primary in-
terest, henceforth to be designated as “principal” interven-
tion, is compared with the outcome of a group subjected to a
reference intervention. To collect sufficient evidence to de-
tect a clinically relevant difference between both interven-
tions, if present, a minimum number of subjects per group
should be included. At the same time, from an ethical point
of view and to warrant an efficient use of resources, it is
also required that the sample size be not larger than needed.
The estimation of the minimum sample size requires the
specification of the minimal difference in outcome (delta)
that would be clinically important to be detected. In addi-
tion, investigators must specify an acceptable type I error
(the probability of detecting a significant difference when
the treatments are really equally effective), an acceptable
type II error (the probability of not detecting a significant
difference when there really is a difference of magnitude
delta or larger, that is, 1 minus power), and an (evidence-
based) estimation of the distribution of the outcome param-
eter in the reference group [1]. Finally, one should explicitly
choose between two-sided or one-sided statistical testing.
Unfortunately, the importance of the latter decision is often
neglected [2–5].
In the two-sided option one is able to detect the pre-
defined relevant difference, if present, in both directions.
That is, if the principal treatment is an amount delta better
than the reference, this will probably be found, but also a
similar advantage of the reference over the principal inter-
vention can be detected. The one-sided option would only
allow a one-sided evaluation, (e.g., whether or not the prin-
cipal is an amount delta better than the reference treatment),
without testing whether the reference is superior to the prin-
cipal intervention.
In the current practice of estimating or reviewing the
needed sample size, two-sided testing is virtually always
used, while one-sided testing is mostly considered unac-
ceptable because it does not account for the possibility that
the reference treatment might be better [6]. However, in or-
der to detect a similar difference in outcome between both
interventions, two-sidedness is paid for by a considerably
larger sample size. For example, accepting a type I error of
0.05 and a type II error of 0.20, and assuming a cumulative
incidence during follow-up of 20% of the primary endpoint
in the reference group, the detection of a clinically relevant
difference in cumulative incidence of 10% favouring the
principal intervention needs a minimum sample size of 157
per group in case of one-sided testing; and of 199 per group
in case of two-sided testing. So, the latter would imply an
 








 157), patients to be in-
cluded in the trial. 
If the incidence of the primary endpoint in the reference
 





sponding numbers of study subjects per group to detect a
similar reduction of 10% would be 305 and 388, respec-
tively [7]. This means that the two-sided approach requires
inclusion of an additional 166 subjects, with a notable dif-
ference in burdening of patients, trial feasibility and cost.
Moreover, if a fatal outcome is studied, in the two-sided
case of the latter example an average of 8 casualties (31 in
the one-sided case versus 39 in the two-sided case) would
be additionally needed to conclude that the principal treat-
ment would be better than the reference.
In choosing between a one-sided or a two-sided approach
it should be recognized that a research hypothesis is not ran-
dom shooting but expresses scientific uncertainty regarding
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a plausible, potentially clinically important effect [8–10].
Before a trial one is not totally ignorant of what is to be
tested. The problem at issue is generally not: “is the princi-
pal treatment better than the reference, or does it equal the
reference, or is it worse than the reference?”. Rather, the
question is “whether the principal treatment is indeed better
than the reference,” considering that an advantage of the
principal over the reference is a reasonable but not suffi-
ciently tested assumption. Thus, a research question is often
hypothesis-driven and typically “one-sided.”
If one cannot exclude the possibility that, unexpectedly,
the principal treatment would be worse than the reference, it
can still be important to test this possibility in a two-sided
approach. However, this is only clinically meaningful if
such a result would change current practice. If the expected
balance between favourable effects and adverse effects of
the principal treatment is such that only clear superiority in
primary endpoints is relevant, not being able to demonstrate
a relevant advantage of the principal treatment is evidence
in favour of the reference.
Even if interventions have similar effects as to primary
outcome, complications, and side effects, their burdens for
the patient may be considerably different. For example, if
carotid endarterectomy in asymptomatic patients is not
shown to produce substantially better outcomes than the
non-surgical approach, the latter will be preferred because it
is less invasive for the patient [11]. And in the absence of a
demonstrated advantage of coumarin over aspirin in pre-
venting stroke in primary care patients with non-valvular
atrial fibrillation, aspirin is the drug of choice since cou-
marin treatment requires frequent blood testing and makes
the patient more dependent on health care [12]. 
Given these considerations, one-sided testing and a cor-
responding sample size estimation can be proposed as the
preferred approach if: (1) the scientific hypothesis to be
tested is obviously one-sided, or if (2) only a clear advan-
tage in effect of the principal over the reference intervention
would have consequences for practice, for example, if the
principal intervention implies a more burdensome regimen
for the patient [13]. Accordingly, if the reference interven-
tion is refraining from treatment or an inactive, placebo
therapy, a useful option is that an active principal interven-
tion should be shown to be clearly better. Therefore, in trials
with “non-treatment” or placebo reference groups, as are of-
ten carried out to test newly developed interventions, the
one-sided approach would be adequate.
Of course, we must recognize that in deciding upon first-
choice treatments in practice, things are more complex than
making inferences based on just one trial. The body of
knowledge generally consists of a mosaic of studies, also
providing insight in the magnitude of effects in relevant
subgroups. Supported by meta-analysis and statistical pool-
ing, this may yield a powerful evidence base for clinical
choices. In fact, this brings the issue of optimal sample size
estimation on a supra-individual trial level: what degree of
uncertainty, based on a systematic review of previous trials,
is sufficient to justify an additional study on the same topic?
Regarding the research hypothesis, prior evidence and the
clinical implications of the treatment under study, should
the sample size and analysis of a new study be based on a
one-sided or a two-sided approach? How large should a new
study be to achieve enough power in addition to the already
performed studies? And how to prospectively design a set
of collaborative studies of sufficient size to be successfully
pooled afterwards?
In the meantime, however, for individual trials, espe-
cially into new interventions not previously studied, a one-




[1] Pocock SJ. Clinical trials, a practical approach. Chichester: John
Wiley & Sons, 1983.
[2] Dunnett CW, Gent M. An alternative to the use of two-sided tests in
clinical trials. Stat Med 1996;15:1729–38.
[3] Peace KE. The alternative hypothesis: one-sided or two-sided? J Clin
Epidemiol 1989;42(5):473–6.
[4] Bland JM, Altman DG. One and two sided tests of significance. BMJ
1994;309:248.
[5] Koch GG. One-sided and two-sided tests and p values. J Biopharm
Stat 1991;1:161–70.
[6] Walker AM. Low power and striking results—a surprise but not a
paradox. N Engl J Med 1995;332:1091–2.
[7] Machin D, Campbell MJ. Statistical tables for the design of clinical
trials. Oxford: Blackwell Scientific Publications, 1987.
[8] Avins AL. Can unequal be more fair? Ethics, subject allocation, and
randomised clinical trials. J Medical Ethics 1998;24:401–8.
[9] Feinstein AR, Concato J. The quest for “power”: contradictory hy-
potheses and inflated sample sizes. J Clin Epidemiol 1998;51:537–45.
[10] Knottnerus JA. Gezondheidszorg in extramurale settings. Ethiek en
Recht in de Gezondheidszorg 1997;IV:151–94.
[11] Benavente O, Moher D, Pham B. Carotid endarterectomy for asymp-
tomatic carotid stenosis: a meta-analysis. BMJ 1998;317:1477–80.
[12] Hellemons BSP, Langenberg M, Lodder J, Vermeer F, Schouten
HJA, Lemmens Th, Ree JW van, Knottnerus JA. Primary prevention
of arterial thromboembolism in non-rheumatic atrial fibrillation in
primary care: randomised controlled trial comparing two intensities
of coumarin with aspirin. BMJ 1999;319:958–64.
[13] Riffenburgh RH. Statistics in medicine. San Diego, CA: Academic
Press, 1999.
